Spots Global Cancer Trial Database for XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
Official Title: Open Label, Uncontrolled Study of XRP9881 in Combination With Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)
Study ID: NCT00386685
Conditions
Study Description
Brief Summary: The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab. The secondary objectives are safety and pharmacokinetic interaction
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Sanofi-Aventis Administrative Office, Diegem, , Belgium
Sanofi-Aventis Administrative Office, Paris, , France
Sanofi-Aventis Administrative Office, Bromma, , Sweden
Sanofi-Aventis Administrative Office, Geneva, , Switzerland
Contact Details
Name: Henri Roche, PhD
Affiliation: Institut Claudius Regaud - Toulouse - France
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
